Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Indiana: - Goshen Center for Cancer Care — Goshen, Indiana
Phase 3 Recruiting Network
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in Indiana: - Indiana University/Melvin and Bren Simon Cancer Center — Indianapolis, Indiana
- Reid Health — Richmond, Indiana
Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRP…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136650
Sites in Indiana: - Urology of Indiana - Carmel ( Site 0055) — Carmel, Indiana
Phase 3 Recruiting Industry
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Sponsor: Clarity Pharmaceuticals Ltd
NCT ID: NCT06056830
Sites in Indiana: - Indiana University School of Medicine — Indianapolis, Indiana
Phase 2, Phase 3 Recruiting Federal
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival…
Sponsor: VA Office of Research and Development
NCT ID: NCT04787744
Sites in Indiana: - Richard L. Roudebush VA Medical Center, Indianapolis, IN — Indianapolis, Indiana
Phase 3 Recruiting Industry
This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection of prosta…
Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
NCT ID: NCT07052214
Sites in Indiana: - Indiana University — Indianapolis, Indiana
Phase 3 Recruiting Industry
Himalayas-1 is a randomized, open-label, global, multicenter phase 3 study evaluating whether the combination of rinzimetostat with darolutamide is more effective compared to physician's choice of control; ARPI (darolutamide or enzalutamid…
Sponsor: ORIC Pharmaceuticals
NCT ID: NCT07723248
Sites in Indiana: - First Urology PSC — Jeffersonville, Indiana
Phase 2, Phase 3 Recruiting Industry
In this study, 196 patients will be randomized 1:1 to either having only the standard of care MRI prior to surgery versus having the standard of care MRI and the PSMA PET scan. PET (and MRI) findings will be validated against whole mount p…
Sponsor: Five Eleven Pharma, Inc.
NCT ID: NCT05381103
Sites in Indiana: - Goodman Hall, Indiana Institute for Biomedical Imaging Sciences, Indiana University School of Medicine — Indianapolis, Indiana
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Indiana: - Reid Health — Richmond, Indiana
Phase 2 Recruiting Federal
This trial tests if the combination of comprehensive metastasis directed therapy delivered by a precision form of external beam radiotherapy (stereotactic ablative radiotherapy), combined with PSMA targeted radiopharmaceutical therapy and …
Sponsor: VA Office of Research and Development
NCT ID: NCT06084338
Sites in Indiana: - Richard L. Roudebush VA Medical Center, Indianapolis, IN — Indianapolis, Indiana
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Indiana: - Exelixis Clinical Site #4 — Indianapolis, Indiana
Phase 1 Recruiting Industry
Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potential treatment for men with advanced prostate cancer. It is given by an injection into the muscle. Men with adv…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT04729114
Sites in Indiana: - Fort Wayne Medical Oncology and Hematology, Inc. — Fort Wayne, Indiana
- First Urology — Jeffersonville, Indiana
Phase 4 Recruiting Industry
The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred t…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05803941
Sites in Indiana: - Parkview Research Center — Fort Wayne, Indiana
NA Recruiting Academic/Other
This is a randomized pilot study of Coronary CT Angiography (CCTA) for coronary atherosclerosis vs. Usual Care in patients with prostate cancer who are either planning to begin, or are currently taking androgen deprivation therapy (ADT) .
Sponsor: Indiana University
NCT ID: NCT05879913
Sites in Indiana: - IU Health Joe and Shelly Schwarz Cancer Center — Carmel, Indiana
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana
- Methodist Hospital — Indianapolis, Indiana
Recruiting Industry
The SONA FUSION Registry is an observational study designed to evaluate the long-term effectiveness and safety of the Sonablate High-Intensity Focused Ultrasound (HIFU) system. This study focuses on adult men who have been treated for loca…
Sponsor: Sonablate
NCT ID: NCT07757490
Sites in Indiana: - Indiana University Medical Center — Indianapolis, Indiana
NA Recruiting Academic/Other
The purpose of this study is to evaluate the tolerability and toxicity of combining two radiation therapy methods for prostate cancer: Elective Pelvic Ultra Hypofractionated Irradiation Treatment (ePUHRT), which is an external beam radioth…
Sponsor: Indiana University
NCT ID: NCT06817668
Sites in Indiana: - Indiana University Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana